Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer

Acta Oncologica

Volumn 35, Issue 4, 1996, Pages 435-439

  Ferrigno, Domenico ^a   Buccheri, Gianfranco ^a  

^a Cardiovascular Anesthesia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANISETRON; MITOMYCIN C; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0030036434     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609109918     Document Type: Article

References (33)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26.
2. Silverberg E, Lubera JA. Cancer statistics, 1988. CA 1988; 38: 5-22.
3. Haskell CM. Chemotherapy and survival of patients with non-small cell lung cancer: a contrary view. Chest 1991; 99: 1325-6.
4. Yokes EE, Bitran JD, Vogelzang NJ. Chemotherapy for non-small cell lung cancer: the continuing challenge. Chest 1991; 99: 1326-8.
5. Buccheri GF. Chemotherapy and survival in non-small cell lung cancer: three years later. Chest 1994; 106: 990-2.
6. Sorensen JB. The role of chemotherapy in non-small cell lung cancer. Radiol Oncol 1994; 28: 386-94.
7. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
8. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-09.
9. Mulshine JL, Glatstein E, Ruckdeschel JC. Treatment of non-small cell lung cancer. J Clin Oncol 1986; 4: 1704-15.
10. Ruckdeschel JC, Metha CR, Salazar OM, Creech RH, Sponzo RW. Chemotherapy for metastatic non-small cell bronchogenic carcinoma. EST 2575, generation III. HAM verus CAMP. Cancer Treat Rep 1981; 65: 959-63.
11. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Crech RH. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, Generation V-A randomized comparison of four cisplatin containing regimens. J Clin Oncol 1985; 3: 72-9.
12. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J. Clin Oncol 1986; 4: 14-22.
13. Chahinian AP, Arnold DJ, Cohen JM, et al. Chemotherapy for bronchogenic carcinoma: methotrexate, doxorubicin, cyclophosphamide, and lomustine. JAMA 1977; 237: 2392-6.
14. World Health Organization. Histologic typing of lung tumors. Am J Clin Pathol 1982; 77: 123-36.
15. International Union Against Cancer. TNM classification of malignant tumours. 4th ed. Geneva: International Union Against Cancer, 1987: 69-73.
16. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press, 1949: 199-205.
17. Mason BA, Catalano RB. Mitomycin, vinblastine and cisplatin combination chemotherapy in non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 1980; 21: 477.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
19. Longo LD, Duffley PL, DeVita VT, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991; 9: 2042-51.
20. Dixon WJ. BMDP: Statistical Software, Berkeley, University of California Press, 1988: 576-83.
21. Kaplan EL, Meier F. Non-parametric estimation for incomplete observations. J Am Sta Assoc 1958; 58: 457-581.
22. Miller VA, Rigas JR, Grant SC, Pisters KMV, Kris MG. New chemotherapeutic agents for non-small cell lung cancer. Chest 1995; 107: 306S-311S.
23. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 794-800.
24. Marino P, Pampallona S. Polychemotherapy in advanced non-small cell lung cancer Lancet 1993; 342: 741.
25. Grilli R, Oxmam AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-72.
26. Ihde DC. Drug therapy: chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-41.
27. Haraf DJ, Devine S, Ihde DC, Vokes EE. The evolving role of systemic therapy in carcinoma of the lung. Semin Oncol 1992; 19 (Suppl. 11): 72-87.
28. Slevin ML, Staquet MJ. Randomized trials in cancer. A critical review by sites. In: Anonymous, ed. Monograph series of the European Organization for Research and Treatment of Cancer, vol. 15, New York: Raven Press, 1986.
29. Buccheri GF. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress? Lung Cancer 1994; 11: 115-7.
30. Buccheri GF, Ferrigno D, Rosso A, Vola F. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990; 6: 87-98.
31. Buccheri GF, Ferrigno D, Vola F, Curcio A. Combination of chemotherapy with methotrexate, adriamycin. cyclophosphamide, and CCNU (MACC) for non-small cell lung cancer: 4-year experience with 92 patients. Oncol 1989; 46: 212-6.
32. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-13.
33. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. BR J Cancer 1995; 2: 366-70.